IGBA Supergroup Gets Audience With WTO
CEO Advisory Committee Outlines ‘Essential Role’ Of Generics And Biosimilars
Executive Summary
The CEO advisory committee established by the IGBA has held its inaugural meeting and begun discussions with the director-general of the World Trade Organization to promote the “essential role” of generics and biosimilars in global health, with the interaction described as a first step towards a continuing dialog.
You may also be interested in...
Jonathan Kimball Named IGBA Chair For 2023
The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.
IGBA Impresses Importance Of Off-Patent Industry On WHO
The IGBA’s CEO advisory committee has met with WHO leaders, including director-general Tedros Adhanom Ghebreyesus, to impress upon them the importance of the generics and biosimilars industry in global patient care and the contribution made during the COVID-19 pandemic.
One Year On, US FDA Generic Drug Cluster Focuses On Facilitating Collaboration
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.